Articles/ Brexit/ Pharma Market Access/ UK & Europe/ Views and analysis Saving the jewel in the crown of ‘UKplc’: Brexit’s impact on pharma Marco Ricci AAR, Brexit, CDF, healthcare, market access, pharma, UK 0 Comment Pharma must embrace the opportunity to shape the UK’s political agenda in its favour. Share X Saving the jewel in the crown of ‘UKplc’: Brexit’s impact on pharma https://pharmaphorum.com/views-and-analysis/saving-jewel-crown-ukplc-brexits-impact-pharma/
Pharma Market Access/ Sales and Marketing/ UK & Europe/ Views and analysis Accelerated Access Review: no panacea for UK pharma Andrew McConaghie AAR, Accelerated Access Review, market access, NHS England, UK 0 Comment What can the AAR do for the UK pharma industry, the health service and patients? Share X Accelerated Access Review: no panacea for UK pharma https://pharmaphorum.com/views-and-analysis/accelerated-access-review-no-panacea-uk-pharma/
Articles/ Cancer/ Views and analysis Is the Cancer Drugs Fund beyond fixing? Linda Banks AAR, CDF 0 Comment Barbara McLaughlan discusses England’s Cancer Drugs Fund (CDF) and suggests ways of securing a new, sustainable assessment and Share X Is the Cancer Drugs Fund beyond fixing? https://pharmaphorum.com/views-and-analysis/is-the-cancer-drugs-fund-beyond-fixing/